Clinical Outcomes of Single-Dose Flomoxef Prophylaxis for Transrectal Prostate Biopsy: A Single-Center Study of 834 Cases
Abstract
OBJECTIVES: Prostate biopsy remains essential for the diagnosis of prostate cancer. Although the transperineal approach is increasingly favored, transrectal prostate biopsy (TRPB) continues to be performed in many institutions. In our institution, single-dose flomoxef (FMOX) was introduced as a prophylactic antibiotic in response to increasing resistance to levofloxacin (LVFX). This study evaluated the effectiveness and microbiological validity of FMOX using real-world clinical data.
METHODS: This retrospective single-center study included 834 patients who underwent TRPB under single-dose intravenous FMOX (1 g) between 2015 and 2024. The clinical outcomes were acute prostatitis and sepsis within 4 weeks after biopsy. Post-biopsy bacteriuria was evaluated as an exploratory microbiological outcome. Pathogen distribution was described among patients with identified organisms, and factors associated with post-biopsy bacteriuria were evaluated using univariable analysis and multivariable logistic regressions.
RESULTS: Among 834 patients, prostatitis occurred in 0.5% of patients; no cases of sepsis were observed. Post-biopsy bacteriuria was observed in 6.5% of patients. Among 31 cases with identified pathogens, Enterococcus faecalis was the most common (54.8%), whereas Escherichia coli accounted for 12.9% of cases. Multivariable analysis identified prostate volume, International Prostate Symptom Score, and constipation as independent risk factors for post-biopsy bacteriuria.…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 834 participants or records.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.